DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy
Partnership integral piece of consortium recently awarded five-year,
The team is part of a consortium that was recently awarded a
“Identification of therapy-relevant biomarkers is a crucial part of breast cancer research, as there are many different biomarkers that could predict treatment response and outcome, and serve as targets for treatment,” said Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at
Leading experts in the fields of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA’s (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low marginal cost.
“More than a million new cancer diagnoses are documented each year, giving researchers vast amounts of data with which to work,” said
About DecisionQ Corporation
DecisionQ is a leader in predictive analytics and machine learning technologies with expertise in the healthcare, life sciences, financial services and security industries. Through the application of its advanced technologies and methods it delivers customers substantial improvements in the speed and quality of decision making by allowing them to quickly turn data into actionable insights. To learn more about DecisionQ visit www.decisionq.com.
Contact: Laura Phillips, Vehr Communications 513.381.8347 firstname.lastname@example.org
SOURCE DecisionQ Corporation